DK2347770T4 - Fremgangsmåde til fremstilling af en injicerbar farmaceutisk tilberedning - Google Patents
Fremgangsmåde til fremstilling af en injicerbar farmaceutisk tilberedning Download PDFInfo
- Publication number
- DK2347770T4 DK2347770T4 DK10183870.4T DK10183870T DK2347770T4 DK 2347770 T4 DK2347770 T4 DK 2347770T4 DK 10183870 T DK10183870 T DK 10183870T DK 2347770 T4 DK2347770 T4 DK 2347770T4
- Authority
- DK
- Denmark
- Prior art keywords
- drug
- spacer
- injectable pharmaceutical
- preparing
- pharmaceutical preparation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Transplantation (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19926154A DE19926154A1 (de) | 1999-06-09 | 1999-06-09 | Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung |
EP06012171A EP1704864B9 (de) | 1999-06-09 | 2000-06-07 | Injizierbare Arzneimittelzubereitung bestehend aus einem Zytostatikum und einer durch einen Spacer gebundenen Maleinimidgruppe. |
Publications (2)
Publication Number | Publication Date |
---|---|
DK2347770T3 DK2347770T3 (da) | 2017-07-03 |
DK2347770T4 true DK2347770T4 (da) | 2020-02-03 |
Family
ID=7910588
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK00945721T DK1183050T3 (da) | 1999-06-09 | 2000-06-07 | Fremgangsmåde til fremstilling af et injicerbart lægemiddelpræparat |
DK10183870.4T DK2347770T4 (da) | 1999-06-09 | 2000-06-07 | Fremgangsmåde til fremstilling af en injicerbar farmaceutisk tilberedning |
DK06012171.2T DK1704864T3 (da) | 1999-06-09 | 2000-06-07 | Injicerbar farmaceutisk tilberedning bestående af et cytostatisk middel og et maleinimid forbundet med en spacer |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK00945721T DK1183050T3 (da) | 1999-06-09 | 2000-06-07 | Fremgangsmåde til fremstilling af et injicerbart lægemiddelpræparat |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK06012171.2T DK1704864T3 (da) | 1999-06-09 | 2000-06-07 | Injicerbar farmaceutisk tilberedning bestående af et cytostatisk middel og et maleinimid forbundet med en spacer |
Country Status (13)
Country | Link |
---|---|
US (5) | US7387771B1 (da) |
EP (3) | EP1704864B9 (da) |
JP (5) | JP5517384B2 (da) |
AT (1) | ATE339225T1 (da) |
AU (1) | AU779697B2 (da) |
CA (1) | CA2374964C (da) |
CY (2) | CY1105701T1 (da) |
DE (2) | DE19926154A1 (da) |
DK (3) | DK1183050T3 (da) |
ES (3) | ES2385230T3 (da) |
PT (3) | PT1183050E (da) |
SI (1) | SI1704864T1 (da) |
WO (1) | WO2000076551A2 (da) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1351611A (zh) | 1999-05-17 | 2002-05-29 | 康久化学公司 | 病毒感染的长效融合肽抑制剂 |
US6514500B1 (en) | 1999-10-15 | 2003-02-04 | Conjuchem, Inc. | Long lasting synthetic glucagon like peptide {GLP-!} |
US6849714B1 (en) | 1999-05-17 | 2005-02-01 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
CA2501421A1 (en) | 1999-05-17 | 2000-11-23 | Conjuchem Inc. | Long lasting exendin-4 |
US7601691B2 (en) | 1999-05-17 | 2009-10-13 | Conjuchem Biotechnologies Inc. | Anti-obesity agents |
US7144854B1 (en) | 1999-09-10 | 2006-12-05 | Conjuchem, Inc. | Long lasting anti-angiogenic peptides |
US6887470B1 (en) | 1999-09-10 | 2005-05-03 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
DE19926154A1 (de) | 1999-06-09 | 2000-12-14 | Ktb Tumorforschungs Gmbh | Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung |
DE19926475A1 (de) * | 1999-06-10 | 2000-12-14 | Ktb Tumorforschungs Gmbh | Träger-Pharmaka-Konjugate |
EP1889639A3 (en) * | 1999-09-07 | 2008-04-09 | ConjuChem Biotechnologies Inc. | Methods and compositions containing succinimide or maleimide derivatives of antineoplastic agents, for producing long lasting antineoplastic agents |
US6706892B1 (en) | 1999-09-07 | 2004-03-16 | Conjuchem, Inc. | Pulmonary delivery for bioconjugation |
CA2383794A1 (en) * | 1999-09-07 | 2001-03-15 | Conjuchem Inc. | Methods and compositions containing succinimide or maleimide derivatives of antineoplastic agents |
US7090851B1 (en) | 1999-09-10 | 2006-08-15 | Conjuchem Inc. | Long lasting fusion peptide inhibitors of viral infection |
US6961567B1 (en) * | 2000-12-07 | 2005-11-01 | Palm, Inc. | Generic activation and registration framework for wireless devices |
US7555571B1 (en) * | 2001-01-05 | 2009-06-30 | Palm, Inc. | Activation of mobile computing device on a cellular network |
EP1355941A2 (en) | 2001-02-02 | 2003-10-29 | ConjuChem, Inc. | Long lasting growth hormone releasing factor derivatives |
US7112567B2 (en) | 2001-02-16 | 2006-09-26 | Conjuchem Inc. | Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders |
US8812398B2 (en) * | 2001-05-08 | 2014-08-19 | Qualcomm Incorporated | Key for a wireless-enabled device |
DE60229677D1 (de) | 2001-05-31 | 2008-12-11 | Conjuchem Biotechnologies Inc | Langwirkende Fusionspeptidinhibitoren gegen HIV-Infektion |
US8435529B2 (en) | 2002-06-14 | 2013-05-07 | Immunomedics, Inc. | Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy |
US7585491B2 (en) | 2002-12-13 | 2009-09-08 | Immunomedics, Inc. | Immunoconjugates with an intracellularly-cleavable linkage |
US7591994B2 (en) | 2002-12-13 | 2009-09-22 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
US8877901B2 (en) | 2002-12-13 | 2014-11-04 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
US9770517B2 (en) | 2002-03-01 | 2017-09-26 | Immunomedics, Inc. | Anti-Trop-2 antibody-drug conjugates and uses thereof |
DE10310082A1 (de) * | 2003-03-07 | 2004-09-16 | Ktb Tumorforschungsgesellschaft Mbh | Protein-bindende Doxorubicin-Peptid-Derivate |
GB0321613D0 (en) * | 2003-09-15 | 2003-10-15 | Drug Discovery Lab As | Compounds |
PL2100904T3 (pl) * | 2004-04-23 | 2011-05-31 | Conjuchem Biotechnologies Inc | Stała faza do zastosowania w sposobie oczyszczania koniugatów albuminy |
DE102005002991A1 (de) * | 2005-01-21 | 2006-07-27 | Rösner Research GmbH & Co.KG | Verfahren zur Herstellung von Albumin-Konjugaten mit Gyrasehemmern |
US10058621B2 (en) | 2015-06-25 | 2018-08-28 | Immunomedics, Inc. | Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers |
US9707302B2 (en) | 2013-07-23 | 2017-07-18 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
US8039432B2 (en) * | 2005-11-09 | 2011-10-18 | Conjuchem, Llc | Method of treatment of diabetes and/or obesity with reduced nausea side effect |
DE102006024528A1 (de) * | 2006-05-23 | 2007-11-29 | Albupharm Heidelberg Gmbh & Co. Kg | Neue, an der Tumorphysiologie orientierte Formulierung eines Zytostatikums, insbesondere von cis-Platin |
DE102007002726A1 (de) * | 2007-01-18 | 2008-07-31 | Bayer Schering Pharma Aktiengesellschaft | Neue Kaskaden-Polymer-Komplexe, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Mittel |
CA2678427C (en) | 2007-02-16 | 2016-06-07 | Ktb Tumorforschungsgesellschaft Mbh | Dual acting prodrugs |
HRP20221259T1 (hr) | 2009-02-13 | 2022-12-09 | Immunomedics, Inc. | Imunokonjugati s intracelularnom vezom koja se može rascijepiti |
EP2289558A1 (en) * | 2009-08-25 | 2011-03-02 | KTB Tumorforschungsgesellschaft mbH | Bisphosphonate-prodrugs |
EP2359802B1 (en) * | 2010-02-12 | 2014-06-18 | Evonik Degussa GmbH | Cosmetic composition containing polyglycerol partial ester |
EP2382993A1 (en) * | 2010-04-19 | 2011-11-02 | KTB Tumorforschungsgesellschaft mbH | Combination of drugs with protein-binding prodrugs |
US9382329B2 (en) | 2012-08-14 | 2016-07-05 | Ibc Pharmaceuticals, Inc. | Disease therapy by inducing immune response to Trop-2 expressing cells |
US9107960B2 (en) | 2012-12-13 | 2015-08-18 | Immunimedics, Inc. | Antibody-SN-38 immunoconjugates with a CL2A linker |
HUE057977T2 (hu) | 2012-12-13 | 2022-06-28 | Immunomedics Inc | Ellenanyagok és SN-38 immunkonjugátumainak dózisai javított hatásossággal és csökkentett toxicitással |
US9492566B2 (en) | 2012-12-13 | 2016-11-15 | Immunomedics, Inc. | Antibody-drug conjugates and uses thereof |
US10744129B2 (en) | 2012-12-13 | 2020-08-18 | Immunomedics, Inc. | Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2 |
US10413539B2 (en) | 2012-12-13 | 2019-09-17 | Immunomedics, Inc. | Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132) |
US9931417B2 (en) | 2012-12-13 | 2018-04-03 | Immunomedics, Inc. | Antibody-SN-38 immunoconjugates with a CL2A linker |
US10137196B2 (en) | 2012-12-13 | 2018-11-27 | Immunomedics, Inc. | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity |
US10206918B2 (en) | 2012-12-13 | 2019-02-19 | Immunomedics, Inc. | Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers |
JP6433913B2 (ja) | 2012-12-13 | 2018-12-05 | サイトレックス コーポレイション | アントラサイクリン製剤 |
KR20150119848A (ko) | 2012-12-21 | 2015-10-26 | 바이오얼라이언스 씨.브이. | 친수성 자기-희생 링커 및 그것의 포합체 |
NZ631022A (en) | 2013-06-05 | 2018-05-25 | Cytrx Corp | Cytotoxic agents for the treatment of cancer |
US11253606B2 (en) | 2013-07-23 | 2022-02-22 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
JP2017528418A (ja) | 2014-06-20 | 2017-09-28 | バイオアライアンス コマンディテール フェンノートシャップ | 抗葉酸受容体アルファ(fra)抗体−薬物コンジュゲート及びその使用方法 |
US9775914B2 (en) | 2014-11-20 | 2017-10-03 | Pharosgen Co., Ltd. | Prodrugs activated by caspase |
CA2981543A1 (en) | 2015-04-22 | 2016-10-27 | Immunomedics, Inc. | Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells |
DK3310800T3 (da) | 2015-06-19 | 2022-02-28 | Centurion Biopharma Corp | Leveringssystem til styret lægemiddelfrigivelse |
US10195175B2 (en) | 2015-06-25 | 2019-02-05 | Immunomedics, Inc. | Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors |
HUE056897T2 (hu) | 2015-12-09 | 2022-03-28 | Univ Wien Med | Monomaleimid-funkcionalizált platinavegyületek rákterápiához |
MX2018008144A (es) | 2016-01-08 | 2018-11-09 | Bioalliance Cv | Anticuerpos tetravalentes anti ligando-1 de glicoproteina p-selectina (psgl-1) y usos de estos. |
US20170224837A1 (en) | 2016-02-10 | 2017-08-10 | Immunomedics, Inc. | Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers |
US10548881B2 (en) | 2016-02-23 | 2020-02-04 | Tarveda Therapeutics, Inc. | HSP90 targeted conjugates and particles and formulations thereof |
CA3016917A1 (en) | 2016-04-27 | 2017-11-02 | Immunomedics, Inc. | Efficacy of anti-trop-2-sn-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors |
CN110392570A (zh) | 2017-03-27 | 2019-10-29 | 免疫医疗公司 | 用沙妥珠单抗格维替康和rad51抑制剂治疗表达trop-2的三阴性乳腺癌 |
WO2018187074A1 (en) | 2017-04-03 | 2018-10-11 | Immunomedics, Inc. | Subcutaneous administration of antibody-drug conjugates for cancer therapy |
WO2019036485A1 (en) | 2017-08-15 | 2019-02-21 | Nantcell, Inc. | ASSOCIATIONS OF CÉTUXIMAB AND HIGH AFFINITY NATURAL KILLER CELLS AND ASSOCIATED METHODS |
JP2021014409A (ja) * | 2017-11-21 | 2021-02-12 | 京都薬品工業株式会社 | タンパク質結合性薬物 |
AU2018375787B2 (en) | 2017-11-30 | 2023-02-23 | Ladrx Corporation | Albumin-binding prodrugs of auristatin E derivatives |
BR112020010989A2 (pt) * | 2017-11-30 | 2020-11-17 | Centurion Biopharma Corporation | sistemas de distribuição de droga à base de maitansinoide |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4251445A (en) | 1978-03-24 | 1981-02-17 | Weltman Joel K | N-succinimidyl haloacetyl aminobenzoates as coupling agents |
EP0024464B1 (en) | 1979-08-29 | 1982-05-12 | Nihon Medi-Physics Co., Ltd. | 2-oxopropionaldehyde bis(thiosemicarbazone)derivatives and their production and use |
US4894226A (en) * | 1986-11-14 | 1990-01-16 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polyproline conjugation |
US5612034A (en) * | 1990-10-03 | 1997-03-18 | Redcell, Inc. | Super-globuling for in vivo extended lifetimes |
US5827819A (en) * | 1990-11-01 | 1998-10-27 | Oregon Health Sciences University | Covalent polar lipid conjugates with neurologically active compounds for targeting |
EP0493745A1 (en) | 1990-12-21 | 1992-07-08 | Dojindo Laboratories | Fluorescent compound, complex, reagent, and specific binding assay employing said reagent |
DE4122210C2 (de) | 1991-07-04 | 1999-04-01 | Deutsches Krebsforsch | Konjugate aus tumoraktiver Verbindung und Serumalbumin sowie Verfahren zu deren Herstellung und ihre Verwendung |
US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
CA2198361A1 (en) | 1994-09-13 | 1996-03-21 | Ramesh K. Prakash | Intracellular delivery of chemical agents to a specific cell type |
IT1282625B1 (it) * | 1996-02-14 | 1998-03-31 | Zambon Spa | Composizione farmaceutica atta ad inibire la formazione di metastasi tumorali |
US5840733A (en) * | 1996-07-01 | 1998-11-24 | Redcell, Canada, Inc. | Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes |
DE19636889A1 (de) | 1996-09-11 | 1998-03-12 | Felix Dr Kratz | Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel |
US5879897A (en) | 1996-09-23 | 1999-03-09 | Wake Forest University | Methods and compositions for the diagnosis of extraesophageal gastric reflux |
ATE296115T1 (de) * | 1997-02-20 | 2005-06-15 | David S Dime | Ortsspezifische arzneimittel verabreichung |
EP1557424A1 (en) | 1997-09-12 | 2005-07-27 | Exiqon A/S | Bi-cyclic nucleoside, nucleotide and oligonucleoide analogues |
AU748496B2 (en) * | 1998-03-23 | 2002-06-06 | Conjuchem, Inc. | Local delivery of long lasting therapeutic agents |
DE19923168A1 (de) | 1999-05-20 | 2000-11-23 | Roche Diagnostics Gmbh | Neue Fluoreszenzfarbstoffe und ihre Verwendung als Fluoreszenzmarker |
DE19926154A1 (de) * | 1999-06-09 | 2000-12-14 | Ktb Tumorforschungs Gmbh | Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung |
DE19926475A1 (de) * | 1999-06-10 | 2000-12-14 | Ktb Tumorforschungs Gmbh | Träger-Pharmaka-Konjugate |
US20060233701A1 (en) | 2005-03-30 | 2006-10-19 | Thomas Parias | Method and apparatus to improve the industrial production of hydrogen-carbon monoxide |
-
1999
- 1999-06-09 DE DE19926154A patent/DE19926154A1/de not_active Ceased
-
2000
- 2000-06-07 CA CA2374964A patent/CA2374964C/en not_active Expired - Lifetime
- 2000-06-07 EP EP06012171A patent/EP1704864B9/de not_active Expired - Lifetime
- 2000-06-07 ES ES06012171T patent/ES2385230T3/es not_active Expired - Lifetime
- 2000-06-07 ES ES10183870T patent/ES2623017T5/es not_active Expired - Lifetime
- 2000-06-07 DK DK00945721T patent/DK1183050T3/da active
- 2000-06-07 DE DE50013468T patent/DE50013468D1/de not_active Expired - Lifetime
- 2000-06-07 EP EP10183870.4A patent/EP2347770B2/de not_active Expired - Lifetime
- 2000-06-07 PT PT00945721T patent/PT1183050E/pt unknown
- 2000-06-07 AU AU59709/00A patent/AU779697B2/en not_active Expired
- 2000-06-07 DK DK10183870.4T patent/DK2347770T4/da active
- 2000-06-07 US US09/980,266 patent/US7387771B1/en not_active Expired - Lifetime
- 2000-06-07 ES ES00945721T patent/ES2269160T3/es not_active Expired - Lifetime
- 2000-06-07 SI SI200031070T patent/SI1704864T1/sl unknown
- 2000-06-07 PT PT101838704T patent/PT2347770T/pt unknown
- 2000-06-07 WO PCT/EP2000/005272 patent/WO2000076551A2/de active IP Right Grant
- 2000-06-07 AT AT00945721T patent/ATE339225T1/de active
- 2000-06-07 EP EP00945721A patent/EP1183050B1/de not_active Expired - Lifetime
- 2000-06-07 JP JP2001502882A patent/JP5517384B2/ja not_active Expired - Lifetime
- 2000-06-07 DK DK06012171.2T patent/DK1704864T3/da active
- 2000-06-07 PT PT06012171T patent/PT1704864E/pt unknown
-
2006
- 2006-03-24 US US11/388,733 patent/US20060233707A1/en not_active Abandoned
- 2006-10-12 CY CY20061101464T patent/CY1105701T1/el unknown
-
2009
- 2009-10-22 US US12/604,093 patent/US8153581B2/en not_active Expired - Fee Related
-
2011
- 2011-04-28 JP JP2011102053A patent/JP5871483B2/ja not_active Expired - Lifetime
-
2012
- 2012-03-07 US US13/414,316 patent/US8846602B2/en not_active Expired - Fee Related
- 2012-08-22 CY CY20121100751T patent/CY1113370T1/el unknown
-
2013
- 2013-12-26 JP JP2013268998A patent/JP2014055192A/ja not_active Withdrawn
-
2014
- 2014-08-26 US US14/469,232 patent/US20150196573A1/en not_active Abandoned
-
2015
- 2015-12-24 JP JP2015252087A patent/JP6290166B2/ja not_active Expired - Lifetime
-
2017
- 2017-11-07 JP JP2017214959A patent/JP6573947B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2347770T4 (da) | Fremgangsmåde til fremstilling af en injicerbar farmaceutisk tilberedning | |
Higashi | Cyclodextrin-based molecular accessories for drug discovery and drug delivery | |
PT781778E (pt) | Novos pro-farmacos de paclitaxel metodo para a sua preparacao bem como a sua utilizacao em quimioterapia selectiva | |
NO20015584D0 (no) | Lantidsvarende insulintrofiske peptider | |
EA200800657A1 (ru) | Способ приготовления очищенных конъюгатов лекарственных средств | |
DK1076644T3 (da) | N-Substituerede aminotetraliner som ligander for neutopeptid Y Y5-receptoren, der er nyttig til behandling af fedme og andre lidelser | |
DE50015623D1 (de) | Kovalent verbrückte insulindimere | |
DE3481170D1 (de) | Neue galenische zubereitungsformen von oralen antidiabetika und verfahren zu ihrer herstellung. | |
CO5190688A1 (es) | Formas farmaceuticas de administracion oral al menos parcialmente retardadas cuya sustancia activa tramadol se encuentra al menos parcialmente en forma de compuesto formado in situ con una hidrosolubilidad 100 mg/ml, y procedimientos para su preparac | |
EA200970726A1 (ru) | Твердый препарат, содержащий алоглиптин и пиоглитазон | |
ATE284861T1 (de) | N-aralkylaminotetraline als neuropeptid-y-y5- rezeptorliganden | |
DK1158962T3 (da) | Fremgangsmåde til fremstilling af faste cyclodextrinholdige doseringsformer | |
WO2001045678A3 (de) | Arzneimittel, verfahren zu dessen herstellung und dessen verwendung | |
ATE534656T1 (de) | Neue oligosaccharide, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen | |
DK1171101T3 (da) | Fremgangsmåde til fremstilling af en vanduoplöselig amorf depotmatrix | |
AU2002327307A1 (en) | Clathrates of butylphtualide with cyclodextrin or its derivatives, a process for their preparations and the use there of | |
WO2003063824A3 (en) | Pharmaceutical composition | |
BR0013106A (pt) | Composição farmacêutica flutuante, comprimido, e processo de prepapação de um comprimido. | |
DK1263413T3 (da) | Fremgangsmåde til fremstilling af faste dispersioner | |
BR0309853A (pt) | Sistema mono-compartimentar de liberação de medicamento por controle osmótico e processo para sua preparação | |
WO2020219880A3 (en) | Cyclodextrin supramolecular scaffolds and uses thereof | |
WO2006029150A3 (en) | Endogenously-formed conjugate of albumin | |
PT1150716E (pt) | Composicao farmaceutica de proteinas hedgehog hidrofobicamente modificadas e sua utilizacao | |
AU2001284189A1 (en) | Modified release formulation | |
Banfi et al. | Design and synthesis of heterocycle fused enediyne prodrugs activable at will |